Halozyme’s ENHANZE™ drug delivery technology platform is based on our patented recombinant human hyaluronidase enzyme (rHuPH20), which removes traditional limitations on the volume of biologics and drugs that can be delivered subcutaneously, or just under the skin.
The delivery platform has been shown in studies to significantly reduce health care practitioner time required for drug administration.
By using our ENHANZE platform, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously, potentially providing a better patient experience. ENHANZE might also improve subcutaneous biologics by reducing the need for multiple injections. Halozyme continues to seek additional partnerships with biopharmaceutical companies that market drugs requiring or benefiting from injection via the subcutaneous route of administration. Halozyme currently has ENHANZE™ Technology partnerships with Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly.
For more information on partnering with Halozyme, please contact a member of the Business Development Team.